Every day, we strive to discover, develop and trial new ways to enhance patient comfort, improve treatment outcomes and help patients live better and healthier lives.
Survival rates are our why. It’s why we’ve created innovation to end the need for painful, repeat biopsies. It’s why we’ve developed our market leading CD8 ImmunoPET imaging agent that provides full body scans; And it’s why we created RPT, to accelerate the healing process through advanced radiation therapy technology.
It’s also why, in the future, we’ll continue to add to our range of radiopharmaceutical products to meet more unique medical needs and continue to merge biotech and pharmaceutical innovations for greater clarity and comfort.
Read on to discover more about RPT, our theranostic solution based on our minibody and cys-diabodies platform technologies.
RPT uses targeted microdoses of radiation to combat cancer. Our platform technologies have double the ability. First, they're ideal imaging agents and with our ImmunoPET Imaging binding to CD8 cells, they deliver precise insight and head-to-toe body scans. Second they provide the ideal platform to generate best in indication RPT treatment because they achieve:
By taking the middle ground between the size of a small molecule/peptide and an antibody, our treatment has a longer time in blood-pool to distribute the drug into cancer tissues and is able to penetrate further into tumors than larger long-circulating antibodies.
Relative to antibodies, our minibodies and cys-diabodies reduce off target radiation dose related toxicities.
By maintaining an antibody-like variable domain, the highly selective tumor binding associated with antibodies and not found with most small molecules is kept.